Using the cancer risk management model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada

Current Oncology

Volumn 23, Issue , 2016, Pages S56-S63

  Popadiuk, C ^a   Gauvreau, C L ^b   Bhavsar, M ^b   Nadeau, C ^c   Asakawa, K ^c   Flanagan, W M ^c   Wolfson, M C ^d   Coldman, A J ^b   Memon, S ^b   Fitzgerald, N ^b   Lacombe, J ^b   Miller, A B ^e  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Canadian Partnership Against Cancer   (Canada)

^c STATISTICS CANADA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; Cervical cancer; Cytology; HPV DNA; Human papillomavirus; Modelling; Screening

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; BIOPSY; CANADA; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; CYTOLOGY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HYSTERECTOMY; MATHEMATICAL MODEL; NONHUMAN; PAPILLOMAVIRIDAE; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER;

EID: 84959348410     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.23.2991     Document Type: Article

References (35)

1. Dickinson J, Tsakonas E, Conner Gorber S, et al. on behalf of the Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer CMAJ 2013;185:35-45.
2. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health 2012;12:992.
3. Canadian Partnership Against Cancer (cpac). Cervical Cancer Screening in Canada: Monitoring Program Performance 2009-2011. Toronto, ON: cpac; 2013.
4. Berkhof J, Coupe VM, Bogaards JA, et al. The health and economic effects of hpv dna screening in the Netherlands. IntJ Cancer 2010;127:2147-58.
5. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on hpv testing in primary cervical cancer screening. IntJ Cancer 2006;119:1095-101.
6. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. on behalf of the Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus dna versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
7. Ronco G, Dillner J, Elfstrom KM, et al. on behalf of the International HPV Screening Working Group. Efficacy of hpv-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
8. Mendes D, Bains I, Vanni T, Jit M. Systematic review of model-based cervical screening evaluations. BMC Cancer 2015;15:334.
9. Pasquale L, Giorgi Rossi P, Carozzi F, et al. Cervical cancer screening with hpv testing in the Valcamonica (Italy) screening programme. J Med Screen 2015;22:38-48.
10. Bennet N. UK pilot of hpv primary screening for cervical cancer. Lancet Oncol 2012;13:e288.
11. Miller AB, Gribble S, Nadeau C, et al. Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (crmm)—human papillomavirus and cervical components. J Cancer Policy 2015;4:1-6.
12. Habbema D, De Kok IM, Brown ML. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q 2012;90:5-37.
13. Nahvijou A, Hadji M, Marnani AB, et al. A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. Asian Pac J Cancer Prev 2014;15:8229-37.
14. Fitzgerald NR, Flanagan WM, Evans WK, Miller AB on behalf of the Canadian Partnership Against Cancer Cancer Risk Management Lung Cancer Working Group. Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals. Scand J Work Environ Health 2015;41:407-12.
15. Evans W, Wolfson MC, Flanagan WM, et al. Canadian cancer risk management model: evaluation of cancer control. Int J Technol Assess Health Care 2013;29:131-9.
16. Flanagan W, Evans WK, Fitzgerald NR, Goffin JR, Miller AB, Wolfson MC. Performance of the cancer risk management model lung cancer screening module. Health Rep2014;26:11-18.
17. Murphy J, Kennedy E, Dunn S, et al. Cervical Screening. Toronto, ON: Cancer Care Ontario; 2011.
18. Coldman AJ, Phillips N, van Niekerk D, et al. Projected impact of hpv and lbc primary testing on rates of referral for colposcopy in a Canadian cervical cancer screening program. J Obstet Gynaecol Can 2015;37:412-20.
19. Schiffman M, Solomon D. Findings to date from the ascus-lsil Triage Study (alts). Arch Pathol Lab Med 2003;127:946-9.
20. Van de Velde N, Brisson M, Boily MC. Modeling human papil-lomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007;165:762-75.
21. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of hpv vaccination. Vaccine 2006;24(suppl 3): 171-7.
22. Popadiuk C, Stankiewicz A, Dickinson J, Pogany L, Miller AB, Onysko J. Invasive cervical cancer incidence and mortality among Canadian women aged 15 to 29 and the impact of screening. J Obstet Gynaecol Can 2012;34:1167-76.
23. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
24. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116:1373-80.
25. Marrett LD, Frood J, Nishri D, Ugnat AM on behalf of the Cancer in Young Adults in Canada Working Group. Cancer incidence in young adults in Canada: preliminary results of a cancer surveillance project. Chronic Dis Can 2002;23:58-64.
26. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
27. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the hpv vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
28. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206:1645-51.
29. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. iarc Working Group on Evaluation of Cervical Cancer Screening Programmes. Br Med J (Clin Res Ed) 1986;293:659-64.
30. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
31. Dickinson JA, Miller AB, Popadiuk C. When to start cervical screening: epidemiological evidence from Canada. BJOG 2014;121:255-60.
32. Dinkelspiel H, Fetterman B, Poitras N, et al. Screening history preceding a diagnosis of cervical cancer in women age 65 and older. Gynecol Oncol2012;126:203-6.
33. Rositch AF, Silver MI, Gravitt PE. Cervical cancer screening in older women: new evidence and knowledge gaps. PLoS Med 2014;11:e1001586.
34. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98.
35. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of hpv vaccine effectiveness: a comparative model-based analysis. Vaccine 2010;28:5473-84.